Loading...
XNAS
BLRX
Market cap26mUSD
Jul 09, Last price  
4.92USD
1D
13.63%
1Q
102.47%
Jan 2017
-64.35%
IPO
-94.13%
Name

BioLine RX Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
13.58
EPS
—
Div Yield, %
—
Shrs. gr., 5y
161.70%
Rev. gr., 5y
%
Revenues
29m
+502.92%
31,894,11463,909,000113,160,000113,160,0000000000004,800,00028,940,000
Net income
-9m
L-84.79%
2,096,9610000-14,400,000-15,841,000-24,352,000-18,507,000-26,806,000-30,932,000-28,144,000-18,872,000-60,614,000-9,221,000
CFO
-44m
L+94.06%
11,463,1100000-14,168,000-14,513,000-20,547,000-24,192,000-22,666,000-23,206,000-23,573,000-26,240,000-22,608,000-43,873,000

Profile

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
URL
https://www.biolinerx.com/
IPO date
Jan 30, 2007
Employees
49
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
28,940
502.92%
4,800
 
Cost of revenue
46,952
47,441
29,811
Unusual Expense (Income)
NOPBT
(18,012)
(42,641)
(29,811)
NOPBT Margin
Operating Taxes
1,000
(6,079)
Tax Rate
NOPAT
(18,012)
(42,642)
(23,732)
Net income
(9,221)
-84.79%
(60,614)
221.18%
(18,872)
-32.94%
Dividends
Dividend yield
Proceeds from repurchase of equity
16,357
14,089
14,359
BB yield
-95.69%
-209.59%
-707.52%
Debt
Debt current
5,001
3,673
1,969
Long-term debt
11,642
9,736
12,511
Deferred revenue
Other long-term liabilities
11,932
4,509
Net debt
(2,919)
(29,585)
(36,602)
Cash flow
Cash from operating activities
(43,873)
(22,608)
(26,240)
CAPEX
(53)
(297)
(316)
Cash from investing activities
29,374
1,444
4,006
Cash from financing activities
20,658
15,056
20,438
FCF
(17,477)
(42,032)
(23,947)
Balance
Cash
19,562
42,994
51,082
Long term investments
Excess cash
18,115
42,754
51,082
Stockholders' equity
(345,599)
(342,259)
(289,543)
Invested Capital
374,100
379,005
357,217
ROIC
ROCE
EV
Common stock shares outstanding
1,198,108
64,224
51,597
Price
0.01
-86.37%
0.10
166.10%
0.04
-71.08%
Market cap
17,093
154.28%
6,722
231.22%
2,029
-66.23%
EV
14,174
(22,863)
(34,573)
EBITDA
(13,947)
(41,257)
(29,157)
EV/EBITDA
0.55
1.19
Interest
9,074
2,169
2,158
Interest/NOPBT